Europe Virology Market
No. of Pages: 202 | Report Code: TIPRE00025736 | Category: Life Sciences
No. of Pages: 202 | Report Code: TIPRE00025736 | Category: Life Sciences
The Europe virology market includes the consolidated markets for France, Germany, United Kingdom, Spain, Italy, and Rest of Europe. Europe occupies a significant position in the virology market and is expected to record vigorous growth rate during the forecast period. The growth of the market is attributed by the products developments done by the companies in the country like Germany and UK, strong research, and development activities, and increasing funding for research on emerging diseases. Influenza is a fatal disease for older people with chronic diseases. The mortality and morbidity of influenza are high in Germany. As per the Max-Planck Institute, around 13,600 people die during every flu season, and many deaths are from the older population. In October 2020, to reduce the risk of simultaneous influenza and COVID-19 outbreaks, Germany ordered an additional 6 million doses of flu vaccine. Also, as per The Robert Koch Institute, in 2019, an increase in Hepatitis E and leptospirosis cases was observed due to increased awareness of these diseases by physicians and increased laboratory testing. Germany has been at the forefront of developing new technologies and therapeutics due to its well-developed infrastructure and high investment. The presence of eminent research institutes has led to the launch of innovative therapeutics. Increasing product launches is the major factor driving the growth of the Europe virology market.
Emerging virus epidemics occur unexpectedly and demand rapid action to stop the disease from spreading. The most recent outbreak of COVID-19 worldwide highlights the need developing diagnostics, vaccines, and antiviral drugs on an urgent basis. As COVID-19 belongs to the coronavirus family, much research into MERS and the development of vaccines against it enabled the rapid advancement of vaccines against COVID-19. Therefore, developing prototype vaccines against potential viruses could greatly accelerate the development of vaccines against any emerging pandemic. For instance, Before COVID-19, The Coalition for Epidemic Preparedness Innovations (CEPI) had developed a robust portfolio of MERS vaccine candidates and invested more than US$140 million to MERS vaccine development, which later laid the groundwork for rapid response to COVID-19 and enabled rapid COVID-19 vaccine development, including the Oxford vaccine. Also, CEPI established a collaboration with the University of Oxford in 2018 to develop a vaccine against MERS using their ChadOx vaccine platform. CEPI provided additional funding to the University of Oxford to adapt this platform technology to develop a vaccine against COVID-19. To scale the manufacture of their COVID-19 vaccine candidate, the University of Oxford subsequently partnered with AstraZeneca, who committed to producing the vaccine on a non-profit basis during the pandemic. Therefore, the pandemic preparedness has helped launch vaccines in a short period, further emphasizing the need for more investment in emerging virus’s research. Europe has been investing in the research of emerging viruses for a long time. The Centre has contributed expertise to recent Ebola outbreaks and is now working on COVID-19. In addition, Vaccine approvals have raised hopes of eventually overcoming the pandemic. However, recent outbreaks and the emergence of new strains of the virus affect the economic outcomes, and a post-pandemic will require governments and the private sector to make long-lasting commitments to global epidemic and pandemic preparedness.
Strategic insights for the Europe Virology provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,208.26 Million |
| Market Size by 2028 | US$ 1,521.97 Million |
| Global CAGR (2021 - 2028) | 3.4% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Virology refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The virology market in Europe is expected to grow from US$ 1,208.26 million in 2021 to US$ 1,521.97 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2021 to 2028. Plant-derived vaccines and biopharmaceuticals do not need costly fermentation and purification systems and other costs associated with cold storage, transportation, and sterile distribution when administered orally. In general, chloroplasts deliver high levels of vaccine antigen expression against bacterial, viral, and protozoan pathogens and biopharmaceuticals and the containment of transgenes by maternal inheritance. In the past eight years, the chloroplast system for therapeutic protein expression has been established. Also, the recent development of an efficient lettuce chloroplast system for oral delivery is a significant advancement. Moreover, at-home health diagnostics is gaining popularity among patients. As a response to the virology market, players are developing at-home test kits that help in easy and quick diagnosis and help in taking immediate medical treatment.
The Europe virology market is segmented on the bases of type, application, end user, and country. Based on type, the market is segmented into diagnostic test, viral infection controlling techniques, antiviral therapeutics, and interferons. The antiviral therapeutics segment dominated the market in 2020, and viral infection controlling techniques segment is expected to be the fastest growing during the forecast period. The diagnostic test segment is further categorized into DNA virus testing, RNA virus testing, others. Similarly, the viral infection controlling techniques is bifurcated into active prophylaxis, and passive prophylaxis. Likewise, the antiviral therapeutics segmented is categorized into virucidal agents, antiviral agents, immunomodulators, and interferons. On the basis of application, the virology market is segmented into skin and soft tissue infections, respiratory tract infections, GI tract infections, sexually transmitted diseases, urinary tract infections, and others. The respiratory tract infections segment dominated the market in 2020, and is expected to be the fastest growing during the forecast period. On the basis of end user, the virology market is segmented into hospitals, diagnostic laboratories, pharmaceutical and biotechnological companies, and research and academic institutes. The hospitals segment dominated the market in 2020, and diagnostic laboratories segment is expected to be the fastest growing during the forecast period.
A few major primary and secondary sources referred to for preparing this report on the virology market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson and Johnson Services, Inc.; QIAGEN; Siemens AG; and Thermo Fisher Scientific Inc. are among others.
The Europe Virology Market is valued at US$ 1,208.26 Million in 2021, it is projected to reach US$ 1,521.97 Million by 2028.
As per our report Europe Virology Market, the market size is valued at US$ 1,208.26 Million in 2021, projecting it to reach US$ 1,521.97 Million by 2028. This translates to a CAGR of approximately 3.4% during the forecast period.
The Europe Virology Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Virology Market report:
The Europe Virology Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Virology Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Virology Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Virology Market
